MOTT DAVID M

Average Profitability
<0.0001%
Insider Buys Quantity
25
Insider Buys Sum
$313.04M
Insider Sells Quantity
3
Insider Sells Sum
$138.46M

Insider Activity of MOTT DAVID M

According to the SEC Form 4 filings, MOTT DAVID M, being in a position of

  1. director at Ardelyx, Inc.,
    оver the last 12 months, has bought 215868 shares for $996,598, and sold 0 shares,
    over all time since 2015-06-05, has bought 7956852 shares for $70.66M, and sold 0 shares.

The largest purchase of all time was on 2018-09-07 and amounted to 30000000 shares of Adaptimmune Therapeutics plc for $50M.

The largest sale of all time was on 2017-11-20 and amounted to 5641032 shares of Appian Corporation for $109.94M.

Biography of MOTT DAVID M

No biography is available at this moment.

2024-11-13PurchaseArdelyx, Inc.
ARDX
director
215,868
0.0924%
$4.62$996,598+9.89%
2022-11-17PurchaseArdelyx, Inc.
ARDX
director
567,000
0.3666%
$1.76$1M+112.21%
2021-09-23SaleNovavax, Inc.
NVAX
director
24,961
0.0328%
$252.90$6.31M-71.35%
2020-12-10PurchaseArdelyx, Inc.
ARDX
director
170,000
0.1864%
$5.89$1M+13.86%
2020-06-25PurchaseArdelyx, Inc.
ARDX
director
68,373
0.0772%
$6.96$476,040-3.97%
2020-06-24PurchaseArdelyx, Inc.
ARDX
director
72,598
0.0821%
$6.75$489,862-0.82%
2020-06-22PurchaseArdelyx, Inc.
ARDX
director
4,673
0.005%
$6.75$31,525-6.67%
2020-04-07PurchaseMersana Therapeutics, Inc.
MRSN
director
1.08M
1.2807%
$5.59$6.02M+153.23%
2020-01-24PurchaseAdaptimmune Therapeutics plc
ADAP
7.5M
1.0346%
$0.67$5M+34.69%
2019-07-22PurchaseMirum Pharmaceuticals, Inc.
MIRM
10 percent owner
900,000
2.6907%
$7.50$6.75M+5.09%
2019-05-09PurchaseTrevi Therapeutics, Inc.
TRVI
10 percent owner
5M
34.6117%
$10.00$50M-42.9%
2019-05-07PurchaseRegulus Therapeutics Inc.
RGLS
10 percent owner
1.14M
6.1239%
$1.08$1.23M-40%
2019-03-05PurchaseMersana Therapeutics, Inc.
MRSN
7.5M
23.242%
$4.00$30M-3.05%
2018-09-07PurchaseAdaptimmune Therapeutics plc
ADAP
30M
4.8721%
$1.67$50M-57.66%
2018-03-27PurchaseAdaptimmune Therapeutics plc
ADAP
12M
2.1988%
$1.92$23M-12.28%
2018-03-26PurchaseAdaptimmune Therapeutics plc
ADAP
1.14M
0.2007%
$1.90$2.18M-14.01%
2018-03-23PurchaseAdaptimmune Therapeutics plc
ADAP
588,180
0.1062%
$1.95$1.14M-12.52%
2018-03-22PurchaseAdaptimmune Therapeutics plc
ADAP
1.74M
0.308%
$1.90$3.31M-12.12%
2018-03-21PurchaseAdaptimmune Therapeutics plc
ADAP
209,688
0.0355%
$1.81$379,640-10.61%
2017-11-27SaleAppian Corporation
APPN
10 percent owner
1.14M
2.1156%
$19.49$22.2M+42.78%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.